|
1.
|
|
8 p, 256.7 KB |
Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening
/
Román, R. (Institut Municipal d'Investigació Mèdica (Barcelona)) ;
Sala, Maria (Institut Municipal d'Investigació Mèdica (Barcelona)) ;
Salas, D. (Centre Superior d'Investigació en Salut Pública, València) ;
Ascunce, N. (Instituto de Salud Pública de Navarra) ;
Zubizarreta, R. (Conselleria de Sanidade de la Xunta de Galicia) ;
Castells, Xavier (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Background: Reducing the false-positive risk in breast cancer screening is important. We examined how the screening-protocol and women's characteristics affect the cumulative false-positive risk. Methods: This is a retrospective cohort study of 1 565 364 women aged 45-69 years who underwent 4 739 498 screening mammograms from 1990 to 2006. [...]
2011 -  10.1093/annonc/mdr032
Annals of oncology, Vol. 23 (march 2011) , p. 104-111
|
|
|
2.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, T (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D C (The West Clinic, Memphis, USA) ;
Obermannová, R (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G (St. Laszlo Hospital, Budapest, Hungary) ;
Prausová, J (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
Garcia-Carbonero, R (Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain) ;
Ciuleanu, T (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, P (Hospital General Univ Gregorio Marañón, Madrid, Spain) ;
Cohn, A L (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E (Univ Hospital Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ;
Yamazaki, K (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, S (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ;
Kim, T W (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A (Mayo Clinic, Phoenix, USA) ;
O'Connor, J (Instituto Alexander Fleming, Buenos Aires, Argentina) ;
Taieb, J (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S R (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, R R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, J (Universitat Autònoma de Barcelona. Departament de Medicina)
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
3.
|
|
9 p, 325.6 KB |
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study
/
Van Cutsem, E (Division of Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ;
Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ;
Lenz, H J (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ;
Lonardi, S (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ;
Falcone, A (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ;
Limón, M L (Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain) ;
Saunders, M (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ;
Sobrero, A (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ;
Park, Y S (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ;
Ferreiro, R (Department of Clinical Oncology, Ramón y Cajal Hospital, Madrid, Spain) ;
Hong, Y S (Department of Oncology, Asan Medical Center, Seoul, South Korea) ;
Tomasek, J (Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic) ;
Taniguchi, H (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ;
Ciardiello, F (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ;
Stoehr, J (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ;
Oum'Hamed, Z (Boehringer Ingelheim France S.A.S, Reims, France) ;
Vlassak, S (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ;
Studeny, M (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ;
Argiles, G (VHIO) ;
Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963
|
|
|
4.
|
|
8 p, 500.4 KB |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
/
Siena, S (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Sartore-Bianchi, A (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Garcia-Carbonero, R (Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO, CIBERONC, Universidad Complutense, Madrid, Spain) ;
Karthaus, M (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ;
Smith, D (Department of Gastroenterology, University Hospital of Bordeaux, Hopital Haut Levaeque, Bordeaux, France) ;
Tabernero, J (Universitat Autònoma de Barcelona) ;
Van Cutsem, E (KU Leuven, Leuven, Belgium) ;
Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ;
Boedigheimer, M (Amgen Inc., Thousand Oaks, CA, USA) ;
Ang, A (Amgen Inc., Thousand Oaks, CA, USA) ;
Twomey, B (Amgen Inc., Thousand Oaks, CA, USA) ;
Bach, B A (Amgen Inc., Thousand Oaks, CA, USA) ;
Jung, A S (Amgen Inc., Thousand Oaks, CA, USA) ;
Bardelli, A (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126
|
|
|
5.
|
|
7 p, 740.6 KB |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
/
Martinez-Marti, Alex (Universitat Autònoma de Barcelona) ;
Felip Font, Enriqueta (Universitat Autònoma de Barcelona) ;
Matito, J (Institut d'Oncologia de la Vall d'Hebron) ;
Mereu, Elisabetta (Universitat Pompeu Fabra) ;
Navarro, A (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, S (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Núria (Universitat Autònoma de Barcelona) ;
Martinez de Castro, A (Vall d'Hebron Institut d'Oncologia) ;
Remon, J (Vall d'Hebron Institut d'Oncologia) ;
Miquel, J M (Vall d'Hebron Institut d'Oncologia) ;
Guillaumet-Adkins, A (Universitat Pompeu Fabra) ;
Nadal, E (Institut Català d'Oncologia) ;
Rodriguez Esteban, Gustavo (Universitat Pompeu Fabra) ;
Arqués, O (Stem Cells and Cancer Group) ;
Fasani, R (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ;
Palmer, H G (Stem Cells and Cancer Group) ;
Vivancos, A (Vall d'Hebron Institut d'Oncologia)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. [...]
2017 - 10.1093/annonc/mdx396
Annals of oncology, Vol. 28 (july 2017) , p. 2451-2457
|
|
|
6.
|
|
7 p, 176.2 KB |
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review
/
García-Foncillas, J (Hospital Universitario Fundación Jiménez Díaz) ;
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Aranda, E (Hospital Reina Sofía, Cordoba) ;
Díaz-Rubio, Eduardo (Universidad Complutense de Madrid. Hospital Clínico San Carlos) ;
López López, R (Hospital Clínico Universitario (Santiago de Compostela)) ;
Taberneroo, J (Universitat Autònoma de Barcelona) ;
Vivancos, A (Vall d'Hebron Institut d'Oncologia)
The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. [...]
2017 - 10.1093/annonc/mdx501
Annals of oncology, Vol. 28 (september 2017) , p. 2943-2949
|
|
|
7.
|
|
9 p, 341.6 KB |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
/
Conteduca, V. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wetterskog, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Sharabiani (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ;
Grande, E. (Hospital Ramon y Cajal. Departamento de Oncologia Médica) ;
Fernandez Perez, M. P. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ;
Jayaram, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Castellano, D. (Hospital Universitario 12 de Octubre. Departamento de Oncologia Médica) ;
Romanel, A. (Università di Trento. Centro di Biologia Integrata) ;
Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Casadio, V. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gurioli, G. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Font, A. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vazquez Estevez, S. (, Hospital Universitario Lucus Augusti. Departamento de Oncologia Médica) ;
González del Alba, A. (Hospital Universitario Son Espases Mallorca. Departament d'Oncologia Médica) ;
Mellado, B. (IDIBAPS Hospital Clinic. Departament d'Oncologia Médica) ;
Fernandez Calvo, O. (Hospital de Ourense. Departamento de Oncologia Médica) ;
Méndez Vidal, M. J. (Hospital Universitario Reina Sofía. Departamento de Oncologia Médica) ;
Climent, M. A. (Instituto Valenciano de Oncología) ;
Duran, I. (Instituto de Biomedicina de Sevilla) ;
Gallardo, E. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez, A. (Hospital de León. Departamento de Oncologia Médica) ;
Santander, C. (Hospital Universitario Miguel Servet. Departamento de Oncologia Médica) ;
Sáez, M. I. (Hospital Regional y Hospital Virgen de la Victoria, Malaga. Departamento de Oncologia Médica) ;
Puente, J. (Hospital Clínico San Carlos. Departamento de Oncologia Médica) ;
Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wingate, A. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Dearnaley, D. (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ;
Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ;
De Giorgi, U. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gonzalez Billalabeitia, E. (Hospital Universitario Morales Meseguer. Departamento de Hematologia y de Oncologia Médica) ;
Attard, G. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Spanish Oncology Genitourinary Group ;
Universitat Autònoma de Barcelona
2632A>G (p. T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3. 26; 95% CI 1. 47-not reached; P¼0. [...]
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516
|
|
|
8.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, S. (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y.H. (Experimental Therapeutics Group) ;
Gris-Oliver, Albert. (Experimental Therapeutics Group) ;
Bonache, S. (Oncogenetics Group) ;
Morancho, B. (Vall d'Hebron Institut d'Oncologia) ;
Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U.M. (Cancer Research UK. Cambridge Institute) ;
Jones, G.N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzman, M. (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, J. (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratú, G. (Cancer Genomics Group) ;
Mancuso, F. (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W.J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital de la Vall d'Hebron) ;
Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J.C. (AstraZeneca (USA)) ;
Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ;
Baselga Torres, Josep, 1959-, (Memorial Sloan Kettering Cancer Center (USA)) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular) ;
Jonkers, J. (Cancer Genomics Group) ;
Diez, Orland (Hospital Vall d'Hebron) ;
O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
|
9.
|
|
8 p, 590.0 KB |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
/
Tabernero, J (Hospital Universitari Vall d'Hebron) ;
Hozak, R R (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Yoshino, T (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ;
Cohn, A L (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ;
Obermannova, R (Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic) ;
Bodoky, G (Oncology, Szent László Hospital, Budapest, Hungary) ;
Garcia-Carbonero, R (CIBERONC, Universidad Complutense, Madrid, Spain) ;
Ciuleanu, T -E (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ;
Portnoy, D C (Oncology, West Clinic, Memphis, USA) ;
Prausová, J (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ;
Muro, K (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan) ;
Siegel, R W (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Konrad, R J (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ;
Ouyang, H (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Melemed, S A (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, D (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F (Oncology, Eli Lilly and Company, Argentina) ;
Van Cutsem, E (KU Leuven, Leuven, Belgium) ;
Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609
|
|
|
10.
|
|
11 p, 388.8 KB |
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
/
Arnold, D (Instituto CUF de Oncologia (I.C.O.), Lisboa) ;
Fuchs, C S (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ;
Taberneroo, J (Universitat Autònoma de Barcelona) ;
Ohtsu, A (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Zhu, A X (Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA) ;
Garon, E B (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ;
Mackey, J R (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ;
Paz Ares, L (Hospital Universitario Doce de Octubre. Departamento de Oncologia Médica) ;
Baron, A D (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ;
Okusaka, T (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ;
Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ;
Yoon, H H (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ;
Das, M (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Ferry, D (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Binder, P (Oncology, Eli Lilly and Company, Bridgewater, USA) ;
Sashegyi, A (Oncology, Eli Lilly and Company, Indianapolis, USA) ;
Chau, I (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
